Allogene Therapeutics Inc
(NAS:ALLO)
$
2.99
-0.01 (-0.33%)
Market Cap: 625.25 Mil
Enterprise Value: 269.70 Mil
PE Ratio: 0
PB Ratio: 1.22
GF Score: 34/100 Allogene Therapeutics Inc at Bank of America NAPA Healthcare Conference Transcript
Jun 15, 2021 / 06:30PM GMT
Release Date Price:
$25.03
(-1.34%)
Jason Matthew Gerberry
BofA Securities, Research Division - MD in US Equity Research
All right. Good day, everybody. Thank you for joining us at the BofA Biotech Summit. It's typically held in Napa. Unfortunately, we're in front of computer screens, but I think there's an end in sight that -- to a future that can be held with some red wine in the evenings. But gentlemen -- and I'm pleased -- I'm Jason Gerberry, biotech -- one of the biotech analysts at BofA. I'm pleased to be introducing Allogene CEO, David Chang; and CFO, Eric Schmidt. And gentlemen, thanks so much for joining us, first off.
Eric Thomas Schmidt
Allogene Therapeutics, Inc. - CFO
Thank you, Jason.
David D. Chang
Allogene Therapeutics, Inc. - Co-Founder, President, CEO & Director
Jason, thank you very much for having us. And as you say -- I mean today is June 15, so things are opening up. So pretty soon, hopefully, we will be back to normal.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot